Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 78 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2015', provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Interstitial Cystitis (Painful Bladder Syndrome) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Interstitial Cystitis (Painful Bladder Syndrome) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Interstitial Cystitis (Painful Bladder Syndrome) Overview 7
Therapeutics Development 8
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview 8
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis 9
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies 10
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes 11
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies 14
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes 15
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development 16
Afferent Pharmaceuticals, Inc. 16
Allergan Plc 17
Aquinox Pharmaceuticals Inc. 18
Kytogenics Pharmaceuticals, Inc. 19
Lipella Pharmaceuticals, Inc. 20
MediPost Co., Ltd. 21
Qu Biologics Inc. 22
Urigen Pharmaceuticals, Inc. 23
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(lidocaine + heparin) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AF-219 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AQX-1125 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
GM-0111 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
human umbilical cord blood-derived mesenchymal stem cells - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
lidocaine hydrochloride - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
LP-08 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
mesalamine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
NEO-5024 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
NEO-5937 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
onabotulinumtoxin A - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pentosan polysulfate sodium - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
QBECP-SSI - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Interstitial Cystitis (Painful Bladder Syndrome) - Recent Pipeline Updates 59
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects 67
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products 68
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones 69
Featured News & Press Releases 69
Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference 69
Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS 70
Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 70
Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC 71
Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis 71
May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms 72
Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis 73
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome 74
Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND 74
Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company's Lead P2X3 Antagonist, AF-219 75
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 77
Disclaimer 78

List of Tables

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2015 8
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Number of Products under Investigation by Universities/Institutes, H2 2015 11
Comparative Analysis by Clinical Stage Development, H2 2015 12
Comparative Analysis by Early Stage Development, H2 2015 13
Products under Development by Companies, H2 2015 14
Products under Investigation by Universities/Institutes, H2 2015 15
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015 16
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan Plc, H2 2015 17
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H2 2015 18
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H2 2015 19
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H2 2015 20
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by MediPost Co., Ltd., H2 2015 21
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Qu Biologics Inc., H2 2015 22
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H2 2015 23
Assessment by Monotherapy Products, H2 2015 24
Assessment by Combination Products, H2 2015 25
Number of Products by Stage and Target, H2 2015 27
Number of Products by Stage and Mechanism of Action, H2 2015 29
Number of Products by Stage and Route of Administration, H2 2015 31
Number of Products by Stage and Molecule Type, H2 2015 33
Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics - Recent Pipeline Updates, H2 2015 59
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H2 2015 67
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H2 2015 68